A Mutually Reinforcing Nanoplatform Orchestrates Immunogenic Ferroptosis and Reprogramming of Tumor-Associated Macrophages for Potent Immunotherapy
Nano Letters · 25.02.2026 · 26 (7) · 2619-2629
DOI: 10.1021/acs.nanolett.5c06063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, online erschienen am 14.02.2026. Verfasst von Linlin Tao und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, No. 639 Longmian Avenue, Nanjing 211198, Chi…. Hauptthemen laut MEDLINE: Ferroptosis, Immunotherapy, Tumor-Associated Macrophages, Sorafenib. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Taishan Scholars Program for Young Expert of Shandong Province, Science and Technology Co-construction Project of National Administration of Traditional Chinese Medicine.
Abstract (Originalsprache)
Solid tumors present formidable barriers to immunotherapy due to low immunogenicity and a highly suppressive microenvironment. This study introduces Hb-DD@SRF, a mutually reinforcing nanoplatform comprising a sorafenib (SRF)-loaded core coated with a dual-targeting hemoglobin (Hb) shell. Upon targeting iron transporters on tumor cells, Fe2+ derived from Hb catalyzes reactive oxygen species (ROS) generation, while acidic conditions trigger SRF release to inhibit glutathione peroxidase 4 (GPX4), synergistically amplifying ferroptosis. This robust process elicits immunogenic cell death to prime T cells. Crucially, Hb-mediated oxygenation precisely offsets the severe hypoxia resulting from SRF, establishing a complementary loop that prevents drug resistance. Furthermore, the platform targets M2 macrophages via the haptoglobin pathway, where oxygen and SRF jointly reprogram them to reverse immunosuppression. This remodeled immunostimulatory microenvironment synergizes with anti-PD-L1 therapy to achieve pronounced suppression of primary and metastatic tumors. Collectively, Hb-DD@SRF orchestrates ferroptosis amplification and comprehensive microenvironment modulation to potentiate antitumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, No. 639 Longmian Avenue, Nanjing 211198, China.
- Department of Clinical Pharmacy, Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, China.
ORCID-Profile: Meirong Huo
Förderung
- National Natural Science Foundation of China
- Taishan Scholars Program for Young Expert of Shandong Province
- Science and Technology Co-construction Project of National Administration of Traditional Chinese Medicine
- Jinan Municipal Science and Technology Plan Project
- National Administration of Traditional Chinese Medicine
- Jinan Municipal Science and Technology Plan
Zitieren
APA
Tao, L., Gong, W., Yang, N., Huang, N., Lv, F., Guo, H., Meng, S., Xu, W., & Huo, M. (2026). A Mutually Reinforcing Nanoplatform Orchestrates Immunogenic Ferroptosis and Reprogramming of Tumor-Associated Macrophages for Potent Immunotherapy. Nano Letters, 26(7), 2619-2629. https://doi.org/10.1021/acs.nanolett.5c06063
Vancouver
Tao L, Gong W, Yang N, Huang N, Lv F, Guo H, et al. A Mutually Reinforcing Nanoplatform Orchestrates Immunogenic Ferroptosis and Reprogramming of Tumor-Associated Macrophages for Potent Immunotherapy. Nano Letters. 2026;26(7):2619-2629. doi:10.1021/acs.nanolett.5c06063
BibTeX
@article{Tao2026,
author = {Tao, Linlin and Gong, Weijiao and Yang, Nan and Huang, Nian and Lv, Fangnan and Guo, Hao and Meng, Siyuan and Xu, Wei and Huo, Meirong},
title = {A Mutually Reinforcing Nanoplatform Orchestrates Immunogenic Ferroptosis and Reprogramming of Tumor-Associated Macrophages for Potent Immunotherapy},
journal = {Nano Letters},
year = {2026},
volume = {26},
number = {7},
pages = {2619--2629},
doi = {10.1021/acs.nanolett.5c06063}
}
EUVIMED